{
    "clinical_study": {
        "@rank": "131112", 
        "arm_group": [
            {
                "arm_group_label": "MT-3995-Low", 
                "arm_group_type": "Experimental", 
                "description": "MT-3995-Low Dose"
            }, 
            {
                "arm_group_label": "MT-3995-High", 
                "arm_group_type": "Experimental", 
                "description": "MT-3995-High Dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of\n      MT-3995 in Subjects with Diabetic Nephropathy"
        }, 
        "brief_title": "Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Nephropathy", 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Nephropathies", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with Type 2 diabetes mellitus and diabetic nephropathy, who have been\n             treated with a stable dose of angiotensin converting enzyme-inhibitor (ACE-I) or\n             angiotensin II receptor blocker (ARB)\n\n          -  Glycosylated haemoglobin (HbA1c) \u226410.5%\n\n          -  Subject with albuminuria\n\n        Exclusion Criteria:\n\n          -  History of Type 1 diabetes, pancreas or \u03b2-cell transplantation, or diabetes secondary\n             to pancreatitis or pancreatectomy.\n\n          -  Serum potassium level <3.5 or >5.0 mmol/L\n\n          -  Subjects who had acute kidney injury within 3 months prior to baseline or have\n             undergone hemodialysis at any time prior to randomisation\n\n          -  Subjects with clinically significant hypotension"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01889277", 
            "org_study_id": "MT-3995-J03"
        }, 
        "intervention": [
            {
                "arm_group_label": "MT-3995-Low", 
                "intervention_name": "MT-3995-Low", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MT-3995-High", 
                "intervention_name": "MT-3995-High", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Diabetic Nephropathy", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kawasaki", 
                    "country": "Japan", 
                    "state": "Kanagawa Pref."
                }, 
                "name": "Koukan Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 in Subjects With Diabetic Nephropathy", 
        "overall_contact": {
            "email": "cti-inq-ml@ml.mt-pharma.co.jp", 
            "last_name": "Clinical Trials Information Desk"
        }, 
        "overall_official": [
            {
                "affiliation": "Division of Nephrology and Endocrinology University of Tokyo School of medicine", 
                "last_name": "Masaomi Nangaku, Professor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Mitsubishi Tanabe Pharma Corporation", 
                "last_name": "Kazuoki Kondou, Adviser", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Frequency and nature of treatment-emergent adverse events and serious adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "20 weeks"
            }, 
            {
                "measure": "Plasma concentrations of MT-3995 and its major metabolite", 
                "safety_issue": "No", 
                "time_frame": "20 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01889277"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change from baseline in Urine albumin-to-creatinine ratio (UACR) and blood pressure", 
            "safety_issue": "No", 
            "time_frame": "20 weeks"
        }, 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}